



US009636314B2

(12) **United States Patent**
Hermansen et al.

(10) **Patent No.:** US 9,636,314 B2
(45) **Date of Patent:** May 2, 2017

(54) **MEDICAMENT FOR TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERTENSION AND/OR METABOLIC SYNDROME**

(71) Applicant: **Stevia Limited**, London (GB)

(72) Inventors: **Kjeld Hermansen**, Ega (DK); **Soren Gregersen**, Ega (DK); **Per Bendix Jeppesen**, Ega (DK)

(73) Assignee: **Stevia Limited**, London (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 99 days.

(21) Appl. No.: **13/917,032**

(22) Filed: **Jun. 13, 2013**

(65) **Prior Publication Data**

US 2014/0094408 A1 Apr. 3, 2014

Related U.S. Application Data

(60) Continuation of application No. 12/187,487, filed on Aug. 7, 2008, now abandoned, which is a continuation of application No. 11/819,659, filed on Jun. 28, 2007, now abandoned, which is a continuation of application No. 10/933,297, filed on Sep. 3, 2004, now abandoned, which is a division of application No. 10/210,787, filed on Jul. 31, 2002, now abandoned, which is a continuation of application No. PCT/DK01/00075, filed on Feb. 1, 2001.

(51) **Int. Cl.**

A61K 31/19 (2006.01)
A61K 31/015 (2006.01)
C07C 13/68 (2006.01)
A61K 31/192 (2006.01)
A61K 31/352 (2006.01)
A61K 31/70 (2006.01)
A61K 31/704 (2006.01)
A61K 36/00 (2006.01)
A61K 36/48 (2006.01)
A61K 38/16 (2006.01)
A61K 45/06 (2006.01)
C07C 61/35 (2006.01)
C07H 15/256 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/19** (2013.01); **A61K 31/015** (2013.01); **A61K 31/192** (2013.01); **A61K 31/352** (2013.01); **A61K 31/70** (2013.01); **A61K 31/704** (2013.01); **A61K 36/00** (2013.01); **A61K 36/48** (2013.01); **A61K 38/16** (2013.01); **A61K 38/168** (2013.01); **A61K 45/06** (2013.01); **C07C 13/68** (2013.01); **C07C 61/35** (2013.01); **C07H 15/256** (2013.01); **C07C 2103/86** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,626,441 A 12/1986 Wolkstein 426/548
5,545,414 A * 8/1996 Behr et al. 424/484

5,980,902 A *	11/1999	Shanmugasundaram et al.	424/774
6,482,448 B2 *	11/2002	Tabor	424/757
7,091,183 B1 *	8/2006	Wolfe et al.	514/6.7
2003/0113390 A1 *	6/2003	Hoie	424/757
2010/0041598 A1	2/2010	Chen	
2010/0093861 A1 *	4/2010	Hermansen et al.	514/557

FOREIGN PATENT DOCUMENTS

CA 2 762 121	8/2001
CN 1195486 A	10/1994
CN 1094580 A	11/1994
CN 1148476	4/1997
CN 1154857 A	7/1997
EP 0565785 A	10/1993
EP 2 330 092	6/2011
JP 06-157302	6/1994
JP 7031407	2/1995
JP 08 325 156 A	10/1996
JP 09052825	2/1997
JP 63 146813 A	6/1998
JP 2002-500677	1/2002
WO WO 01/56959	8/2001
WO WO 02/060419	8/2002
WO WO 2006/116815	11/2006
WO 2008/031439	3/2008

OTHER PUBLICATIONS

Jeppesen et al., "Stevoside and Steviol Stimulate Insulin Secretion from Isolated Mouse Islets" Diabetologia (1996) vol. 39 suppl. A125.*

Elks et al., "Central Adiposity, Systemic Inflammation, and the Metabolic Syndrome" Curr Hypertens Rep (2010) pp. 1-10.*

Hansen, "The metabolic syndrome X" Annals of the New York Academy of Sciences (1999) vol. 892, pp. 1-24.*

Vedavanam et al., "Antioxidant Action and Potential Antidiabetic Properties of an Isoflavonoid-containing Soyabean Phytochemical Extract (SPE)" Phytotherapy Research (1999) vol. 13 pp. 601-608.*

Merriam-Webster's Collegiate Dictionary, Tenth Edition, published 1998 by Merriam-Webster, Incorporated, pp. 924 and 935.*

The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, p. 169.*

Malaisse et al., "Effects of Artificial Sweeteners on Insulin Release and Cationic Fluxes in Rat Pancreatic Islets" Cell Signal. (1998) vol. 10 No. 10, pp. 727-733.*

Merck Manual of Medical Information, Home Edition, 1997, p. 794-795.*

Merck Manual of Medical Information, Home Edition, 1997, p. 788.*

Macho et. al. Endocrine Regulations (34), 119-126, 2000.*

P.B. Jeppesen, et. al. Diabetologie, 1996, 39, Suppl. A125.*

Toskulkao, C. et. al. Toxicology Letters, 1995, 80, 153-159.*

Ponszen, HH. et. al. Clinical Therapeutics, 2000, 22, 709-718.*

DeFronzo, RA. et. al. Journal of Diabetes and Its Complications, 1996, 10, 243-245.*

Curi, et. al., Effect of Stevia Rebaudiana on Glucose Tolerance in Normal Adult Humans, Brazilian J. Med. Biol. Res., 1986, pp. 771-774, vol. 19.

(Continued)

Primary Examiner — Eric Olson

(74) Attorney, Agent, or Firm — Browdy and Neimark, P.L.L.C.

(57)

ABSTRACT

A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.

13 Claims, 13 Drawing Sheets